Abstract
Gastrointestinal stromal tumors (GISTs) have emerged from being poorly defined, treatment-resistant tumors to a well-recognized, well-understood, and treatable tumor entity within only one decade. The understanding of GIST biology has made this tumor a paradigm for molecularly targeted therapy in solid tumors and provides informative insights into the advantages and limitations of so-called targeted therapeutics. Approximately 85% of GISTs harbor activating mutations in KIT or the homologous receptor tyrosine kinase PDGFRA gene. These mutations are an early event in GIST development and the oncoproteins serve as a target for the small molecule tyrosine kinase inhibitors imatinib and sunitinib. The existing and emerging treatment options demand exact morphologic classification and risk assessment. Although, KIT (CD117) immunohistochemistry is a reliable diagnostic tool in the diagnosis of GIST, KIT-negative GISTs, GISTs showing unusual morphology as well as GISTs which progress during or after treatment with imatinib/sunitinib can be a challenge for pathologists and clinicians. This review focuses on GIST pathogenesis, morphologic evaluation, promising new immunohistochemical markers, risk assessment, the role of molecular analysis, and the increasing problem of secondary imatinib resistance and its mechanisms.
Similar content being viewed by others
References
Demetri GD, Benjamin RS, Blanke CD et al (2007) NCCN Task force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5(Suppl 2):S1–S29
Edmonson JH, Marks RS, Buckner JC et al (2002) Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Investig 20(5–6):605–612
Fletcher CD, Berman JJ, Corless C et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathol 33:459–465
Mazur MT, Clark HB (1983) Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 7(6):507–519
Miettinen M, Virolainen M, Maarit Sarlomo R (1995) Gastrointestinal stromal tumors—value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 19(2):207–216
Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577–580
Huizinga JD, Thuneberg L, Kluppel M et al (1995) W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373(6512):347–349
Kindblom L, Ramotti H, Aldenborg F et al (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259–1269
Robinson TL, Sircar K, Hewlett BR et al (2000) Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal. Am J Pathol 156(4):1157–1163
Janeway KA, Liegl B, Harlow A et al (2007) Pediatric KIT wild-type and platelet-derived growth factor receptor alpha wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 67(19):9084–9088
Isozaki K, Hirota S, Nakama A et al (1995) Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. Gastroenterology 109(2):456–464
Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA-activating mutations in gastrointestinal stromal tumors. Science 299(5607):708–710
Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21(23):4342–4349
Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22(18):3813–3825
Hornick JL, Fletcher CD (2002) Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 117(2):188–193
Hornick JL, Fletcher CD (2007) The role of KIT in the management of patients with gastrointestinal stromal tumors. Human Pathol 38(5):679–687
Stenman G, Eriksson A, Claesson-Welsh L (1989) Human PDGFA receptor gene maps to the same region on chromosome 4 as the KIT oncogene. Genes Chromos Cancer 1(2):155–158
Hubbard SR (2004) Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat Rev Mol Cell Biol 5(6):464–471
Pawson T (2002) Regulation and targets of receptor tyrosine kinases. Eur J Cancer 38(Suppl 5):S3–S10
Blume-Jensen P, Claesson-Welsh L, Siegbahn A et al (1991) Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. Embo J 10(13):4121–4128
O’Farrell AM, Abrams TJ, Yuen HA et al (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101(9):3597–3605
Casteran N, De Sepulveda P, Beslu N et al (2003) Signal transduction by several KIT juxtamembrane domain mutations. Oncogene 22(30):4710–4722
Duensing A, Medeiros F, McConarty B et al (2004) Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23(22):3999–4006
Kitayama H, Kanakura Y, Furitsu T et al (1995) Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85(3):790–798
Rossi F, Ehlers I, Agosti V et al (2006) Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci U S A 103(34):12843–12848
Lev S, Blechman J, Nishikawa S et al (1993) Interspecies molecular chimeras of kit help define the binding site of the stem cell factor. Mol Cell Biol 13(4):2224–2234
Maeda H, Yamagata A, Nishikawa S et al (1992) Requirement of c-kit for development of intestinal pacemaker system. Development 116(2):369–375
Duensing A, Joseph NE, Medeiros F et al (2004) Protein kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 64(15):5127–5131
Rubin BP, Singer S, Tsao C et al (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61(22):8118–21
Corless CL, Heinrich MC (2008) Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 3:557–586
Lasota J, Dansonka-Mieszkowska A, Stachura T et al (2003) Gastrointestinal stromal tumors with internal tandem duplications in 3′ end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Path 16(12):1257–1264
Lasota J, Miettinen M (2008) Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 53(3):245–266
Wardelmann E, Losen I, Hans V et al (2003) Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 106(6):887–895
Antonescu CR, Sommer G, Sarran L et al (2003) Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9(9):3329–3337
Miettinen M, Makhlouf H, Sobin LH et al (2006) Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30(4):477–489
Heinrich MC, Owzar K, Corless CL et al (2008) Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26(33):5360–5367
Lasota J, Corless CL, Heinrich MC et al (2008) Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Path 21(4):476–484
Debiec-Rychter M, Wasag B, Stul M et al (2004) Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 202(4):430–438
Medeiros F, Corless CL, Duensing A et al (2004) KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28(7):889–894
Wardelmann E, Hrychyk A, Merkelbach-Bruse S et al (2004) Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn 6(3):197–204
Lasota J, Dansonka-Mieszkowska A, Sobin LH et al (2004) A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 84(7):874–883
Lasota J, Stachura J, Miettinen M (2006) GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest 86(1):94–100
Debiec-Rychter M, Sciot R, Le Cesne A et al (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42(8):1093–1103
Corless CL, Schroeder A, Griffith D et al (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23(23):5357–5364
Hirota S, Ohashi A, Nishida T et al (2003) Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125(3):660–667
Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1):327–337
Ma Y, Cunningham ME, Wang X et al (1999) Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region. J Biol Chem 274(19):13399–13402
Agaimy A, Terracciano LM, Dirnhofer S et al (2009) V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 62(7):613–616
Agaram NP, Wong GC, Guo T et al (2008) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromos Cancer 47(10):853–859
Hostein I, Faur N, Primois C et al (2010) BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol 133(1):141–148
Agaimy A, Wunsch PH, Dirnhofer S et al (2008) Microscopic gastrointestinal stromal tumors in esophageal and intestinal surgical resection specimens: a clinicopathologic, immunohistochemical, and molecular study of 19 lesions. Am J Surg Pathol 32(10):1553–1559
Kawanowa K, Sakuma Y, Sakurai S et al (2006) High incidence of microscopic gastrointestinal stromal tumors in the stomach. Human Pathol 37(12):1527–1535
Corless CL, McGreevey L, Haley A et al (2002) KIT mutations are common in incidental gastrointestinal stromal zumors one centimeter or less in size. Am J Pathol 160(5):1567–1572
Debiec-Rychter M, Lasota J, Sarlomo-Rikala M et al (2001) Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet 128(1):24–30
Fukasawa T, Chong JM, Sakurai S et al (2000) Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor. Jpn J Cancer Res 91(12):1241–1249
El-Rifai W, Sarlomo-Rikala M, Miettinen M et al (1996) DNA copy number losses in chromosome 14: an early change in gastrointestinal stromal tumors. Cancer Res 56(14):3230–3233
Bergmann FGB, Hermanns B et al (1998) Cytogenetic and morphologic characteristics of gastrointestinal stromal tumors. Recurrent rearrangement of chromosome 1 and losses of chromosomes 14 and 22 as common anomalies. Verh Dtsch Ges Pathol 82:275–278
Kim NG, Kim JJ, Ahn JY et al (2000) Putative chromosomal deletions on 9P, 9Q and 22Q occur preferentially in malignant gastrointestinal stromal tumors. Int J Cancer 85(5):633–638
Lasota J, vel Dobosz AJ, Wasag B et al (2007) Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest 87(10):1029–1041
El-Rifai W, Sarlomo-Rikala M, Andersson LC et al (2000) High-resolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor suppressor loci. Genes Chromos Cancer 27(4):387–391
Schurr P, Wolter S, Kaifi J et al (2006) Microsatellite DNA alterations of gastrointestinal stromal tumors are predictive for outcome. Clin Cancer Res 12(17):5151–5157
Belinsky MG, Skorobogatko YV, Rink L et al (2009) High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromos Cancer 48(10):886–896
Nilsson B, Bumming P, Meis-Kindblom JM et al (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103(4):821–829
Goettsch WG, Bos SD, Breekveldt-Postma N et al (2005) Incidence of gastrointestinal stromal tumours is underestimated: results of a nationwide study. Eur J Cancer 41(18):2868–2872
Tryggvason G, Gislason HG, Magnusson MK et al (2005) Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 117(2):289–293
Agaimy A, Wunsch PH, Hofstaedter F et al (2007) Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31(1):113–120
Abraham SC, Krasinskas AM, Hofstetter WL et al (2007) “Seedling” mesenchymal tumors (gastrointestinal stromal tumors and leiomyomas) are common incidental tumors of the esophagogastric junction. Am J Surg Pathol 31(11):1629–1635
Miettinen M, Sobin LH, Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1,765 cases with long-term follow-up. Am J Surg Pathol 29(1):52–68
Prakash S, Sarran L, Socci N et al (2005) Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol 27(4):179–187
Miettinen M, Lasota J, Sobin LH (2005) Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 29(10):1373–1381
Beghini A, Tibiletti MG, Roversi G et al (2001) Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 92(3):657–662
Isozaki K, Terris B, Belghiti J et al (2000) Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 157(5):1581–1585
Kang DY, Park CK, Choi JS et al (2007) Multiple gastrointestinal stromal tumors: clinicopathologic and genetic analysis of 12 patients. Am J Surg Pathol 31(2):224–232
Maeyama H, Hidaka E, Ota H et al (2001) Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 120(1):210–215
Nishida T, Hirota S, Taniguchi M et al (1998) Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 19(4):323–324
O’Riain C, Corless CL, Heinrich MC et al (2005) Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic features. Am J Surg Pathol 29(12):1680–1683
Kleinbaum EP, Lazar AJ, Tamborini E et al (2008) Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. Int J Cancer 122(3):711–718
Pasini B, McWhinney SR, Bei T et al (2008) Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 16(1):79–88
Li FP, Fletcher JA, Heinrich MC et al (2005) Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 23(12):2735–2743
Andersson J, Sihto H, Meis-Kindblom JM et al (2005) NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol 29(9):1170–1176
Maertens O, Prenen H, Debiec-Rychter M et al (2006) Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet 15(6):1015–1023
Miettinen M, Fetsch JF, Sobin LH et al (2006) Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 30(1):90–96
Carney JA (1999) Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 74(6):543–552
Carney JA, Stratakis CA (2002) Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet 108(2):132–139
DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231(1):51–58
Miettinen M, Monihan JM, Sarlomo-Rikala M et al (1999) Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 23(9):1109–1118
Reith JD, Goldblum JR, Lyles RH et al (2000) Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Path 13(5):577–585
Agaimy A, Markl B, Arnholdt H et al (2009) Multiple sporadic gastrointestinal stromal tumours arising at different gastrointestinal sites: pattern of involvement of the muscularis propria as a clue to independent primary GISTs. Virchows Arch 455(2):101–108
Verma P, Corless C, Medeiros F et al (2005) Pleomorphic gastrointestinal stromal tumors: diagnostic and therapeutic implications. Mod Pathol 18(suppl 1):121A, abstract
Antonescu CR, Hornick JL, Nielsen GP et al (2007) Dedifferentiation in gastrointestinal stromal tumor (GIST) to an anaplastic KIT-negative phenotype—a diagnostic pitfall. Mod Pathol 20(suppl 2):11A, abstract
Pauwels P, Debiec-Rychter M, Stul M et al (2005) Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 47(1):41–47
Liegl B, Hornick JL, Antonescu C et al (2009) Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am J Surg Pathol 33(2):218–226
Janeway KA, Albritton KH, Van Den Abbeele AD et al (2009) Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer 52(7):767–771
Heinrich MC, Maki RG, Corless CL et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26(33):5352–5359
Zhang L, Smyrk TC, Young WF Jr et al (2010) Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol 34(1):53–64
Sarlomo-Rikala M, Kovatich A, Barusevicius A et al. (1998). CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Path (11):728–734
Miettinen M, Lasota J (2005) KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 13(3):205–220
Orosz Z, Tornoczky T, Sapi Z (2005) Gastrointestinal stromal tumors: a clinicopathologic and immunohistochemical study of 136 cases. Pathol Oncol Res 11(1):11–21
Liegl B, Hornick JL, Corless C et al (2009) Monoclonal antibody DOG 1.1 shows higher sensitivity than KIT in the diagnosis of Gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 33(3):437–446
West RB, Corless CL, Chen X et al (2004) The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 165(1):107–113
Espinosa I, Lee CH, Kim MK et al (2008) A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 32(2):210–218
Miettinen M, Wang ZF, Lasota J (2009) DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1,840 cases. Am J Surg Pathol 33(9):1401–1408
Blay P, Astudillo A, Buesa JM et al (2004) Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res 10(12 Pt 1):4089–4095
Lee HE, Kim MA, Lee HS et al (2008) Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining. J Clin Pathol 61(6):722–729
Rossi G, Valli R, Bertolini F et al (2005) PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract. Histopathology 46(5):522–531
Peterson MR, Piao Z, Weidner N et al (2006) Strong PDGFRA positivity is seen in GISTs but not in other intra-abdominal mesenchymal tumors: immunohistochemical and mutational analyses. Appl Immunohistochem Mol Morphol 14(4):390–396
Zheng S, Chen LR, Wang HJ et al (2007) Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor. Hepatogastroenterology 54(80):2285–2290
Miselli F, Millefanti C, Conca E et al (2008) PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors. Am J Surg Pathol 32(5):738–743
Yang XH, Wu QL, Yu XB et al (2008) Nestin expression in different tumours and its relevance to malignant grade. J Clin Pathol 61(4):467–473
Parkkila S, Lasota J, Fletcher J A et al. (2010) Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol (in press)
Price ND, Trent J, El-Naggar AK et al (2007) Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A 104(9):3414–9
Sarlomo-Rikala M, Miettinen M (1995) Gastric schwannoma—a clinicopathological analysis of six cases. Histopathology 27(4):355–360
Carlson JW, Fletcher CD (2007) Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 51(4):509–514
Montgomery E, Torbenson MS, Kaushal M et al (2002) Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol 26(10):1296–1301
Lucas DR, al-Abbadi M, Tabaczka P et al (2003) C-Kit expression in desmoid fibromatosis. Comparative immunohistochemical evaluation of two commercial antibodies. Am J Clin Pathol 119(3):339–345
Cessna MH, Zhou H, Sanger WG et al (2002) Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Path 15(9):931–938
Lasota J, Wang ZF, Sobin LH et al (2009) Gain-of-function PDGFRA mutations, earlier reported in gastrointestinal stromal tumors, are common in small intestinal inflammatory fibroid polyps. A study of 60 cases. Mod Path 22(8):1049–56
Schildhaus HU, Cavlar T, Binot E et al (2008) Inflammatory fibroid polyps harbour mutations in the platelet-derived growth factor receptor alpha (PDGFRA) gene. J Pathol 216(2):176–182
Antonescu CR, Nafa K, Segal NH et al (2006) EWS-CREB1: a recurrent variant fusion in clear cell sarcoma—association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res 12(18):5356–5362
Lyle PL, Amato CM, Fitzpatrick JE et al (2008) Gastrointestinal melanoma or clear cell sarcoma? Molecular evaluation of 7 cases previously diagnosed as malignant melanoma. Am J Surg Pathol 32(6):858–866
Fletcher CD, Berman JJ, Corless C et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 10(2):81–89
Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23(2):70–83
Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Human Pathol 39(10):1411–1419
Woodall CE 3rd, Brock GN, Fan J et al (2009) An evaluation of 2,537 gastrointestinal stromal tumors for a proposed clinical staging system. Arch Surg 144(7):670–678
Gold JS, Gonen M, Gutierrez A et al (2009) Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 10(11):1045–1052
Perrone F, Tamborini E, Dagrada GP et al (2005) 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. Cancer 104(1):159–169
Ricci R, Arena V, Castri F et al (2004) Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol 122(1):35–43
Sabah M, Cummins R, Leader M et al (2004) Loss of heterozygosity of chromosome 9p and loss of p16INK4A expression are associated with malignant gastrointestinal stromal tumors. Mod Pathol 17(11):1364–1371
Schneider-Stock R, Boltze C, Lasota J et al (2003) High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol 21(9):1688–1697
Schneider-Stock R, Boltze C, Lasota J et al (2005) Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 11(2 Pt 1):638–645
Steigen SE, Bjerkehagen B, Haugland HK et al (2008) Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway. Mod Path 21(1):46–53
Feakins RM (2005) The expression of p53 and bcl-2 in gastrointestinal stromal tumours is associated with anatomical site, and p53 expression is associated with grade and clinical outcome. Histopathology 46(3):270–279
Nemoto Y, Mikami T, Hana K et al (2006) Correlation of enhanced cell turnover with prognosis of gastrointestinal stromal tumors of the stomach: relevance of cellularity and p27kip1. Pathol Int 56(12):724–731
Pruneri G, Mazzarol G, Fabris S et al (2003) Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation. Mod Path 16(9):886–892
Tornillo L, Duchini G, Carafa V et al (2005) Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest 85(7):921–931
Romeo S, Debiec-Rychter M, Van Glabbeke M et al (2009) Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 15(12):4191–4198
Martinho O, Gouveia A, Silva P et al (2009) Loss of RKIP expression is associated with poor survival in GISTs. Virchows Arch 455(3):277–284
Turkoz HK, Alkan I, Sisman S et al (2009) Cyclooxygenase-2 expression and connection with tumor recurrence and histopathologic parameters in gastrointestinal stromal tumors. APMIS 117(11):825–830
Wei YC, Li CF, Yu SC et al (2009) Ezrin overexpression in gastrointestinal stromal tumors: an independent adverse prognosticator associated with the non-gastric location. Mod Path 22(10):1351–1360
Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4):620–625
Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26(4):626–632
Heinrich MC, Corless CL, Blanke CD et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24(29):4764–4774
Casali PG, Jost L, Reichardt P et al (2008) Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2):ii35–ii38
DeMatteo R, Owzar K, Antonescu C R, et al. (2008). Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the US intergroup phase II trial ACOSOG Z9000. Gastrointestinal Cancer Symposium, Orlando, Florida. Proceedings No. 8, p73
DeMatteo RPACR, Chadaram V, et al. (2005). Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumors (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. J Clin Oncol 23(ASCO Annual Meeting Proceedings. No. 16S, Part I of II (June 1 Supplement))
DeMatteo RP, Ballman KV, Antonescu CR et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097–1104
Lasota J, Miettinen M (2006) KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 23(2):91–102
Fletcher J, Corless C, Dimitrijevic S et al. (2003) Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol (22):3275–3277
Debiec-Rychter M, Cools J, Dumez H et al (2005) Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128(2):270–279
Liegl B, Kepten I, Lee C et al (2008) Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216(1):64–74
Agaram NP, Besmer P, Wong GC et al (2007) Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res 13(1):170–181
Prenen H, Cools J, Mentens N et al (2006) Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12(8):2622–2627
Wardelmann E, Merkelbach-Bruse S, Pauls K et al (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12(6):1743–1749
Antonescu CR, Besmer P, Guo T et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11(11):4182–4190
Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338
Montemurro M, Schoffski P, Reichardt P et al (2009) Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 45(13):2293–2297
Dewaele B, Wasag B, Cools J et al (2008) Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 14(18):5749–5758
Muhlenberg T, Zhang Y, Wagner AJ et al (2009) Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res 69(17):6941–6950
Pantaleo MA, Astolfi A, Di Battista M et al (2009) Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int J Cancer 125(12):2991–2994
Tarn C, Rink L, Merkel E et al (2008) Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 105(24):8387–92
Bauer S, Yu LK, Demetri GD et al (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66(18):9153–9161
Sambol EB, Ambrosini G, Geha RC et al (2006) Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res 66(11):5858–5866
Bauer S, Parry JA, Muhlenberg T et al (2010) Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res 70(1):150–159
Bauer S, Duensing A, Demetri GD et al (2007) KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene 26(54):7560–7568
Ou WB, Zhu MJ, Demetri GD et al (2008) Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors. Oncogene 18:5624–5634
Conflict of interest statement
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liegl-Atzwanger, B., Fletcher, J.A. & Fletcher, C.D.M. Gastrointestinal stromal tumors. Virchows Arch 456, 111–127 (2010). https://doi.org/10.1007/s00428-010-0891-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-010-0891-y